MedTrace Logo

Personalized Medicine in Early Stage Colorectal Cancer: Organ Preservation and Immune Benefit

NCT06251726 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 310

Last updated 2024-02-15

No results posted yet for this study

Summary

The overall aim of this study is to determine whether the Immunoscore associated with histopathological features of endoscopically resected stage T1 colorectal tumors is predictive of locoregional lymph node invasion, in order to better select patients eligible for an organ preservation strategy.

Conditions

Interventions

DIAGNOSTIC_TEST

Immunoscore Colon Test

Immunoscore Colon is an in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated image analysis software to determine CD3+ and CD8 + cell densities in the tumor ant in the invasive margin of the tumor.

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • Ministry of Health, France

    collaborator OTHER_GOV

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Franck Pagès, MD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06251726 on ClinicalTrials.gov